N2OFF: KDJ Death Cross on 15min chart with Bearish Marubozu Candle.
PorAinvest
miércoles, 1 de octubre de 2025, 12:02 pm ET1 min de lectura
NITO--
The acquisition involves N2OFF purchasing shares from existing stakeholders for $700,000 and exchanging additional shares for ownership stakes, ultimately positioning MitoCareX as a wholly owned subsidiary. The agreement includes provisions for milestone-based stock issuances and a commitment from N2OFF to support MitoCareX financially for the first two years post-acquisition. The transaction is expected to close in October 2025, pending final conditions [1].
The approval of the acquisition demonstrates shareholder confidence in N2OFF's strategic direction and growth prospects. However, the acquisition includes terms that may dilute existing shareholders, as the sellers will be entitled to 30% of N2OFF's financing proceeds and milestone-based issuances of up to 25% of common stock. Additionally, the press release reveals a potential conflict of interest, as key individuals from N2OFF are also involved with SciSparc, raising concerns about governance and decision-making transparency regarding the acquisition [1].
N2OFF's commitment to financially support MitoCareX with an initial cash investment of $1,000,000 and ongoing operations support increases the company's financial obligations, which may affect its capital allocation and operational focus [1].
The 15-minute chart for N2OFF on October 1, 2025, at 12:00, indicated a KDJ Death Cross and Bearish Marubozu pattern, suggesting a shift in momentum towards the downside. Sellers are currently in control of the market, and bearish momentum is likely to continue .
According to the 15-minute chart for N2OFF, a KDJ Death Cross and Bearish Marubozu pattern was observed on October 1, 2025 at 12:00. This indicates a shift in momentum towards the downside, with a potential for further price decreases. Sellers are currently in control of the market, and bearish momentum is likely to continue.
N2OFF, Inc. (NASDAQ: NITO), a cleantech company focused on solar energy assets, has received approval from its stockholders to acquire MitoCareX Bio Ltd., a biotech firm specializing in cancer therapeutics through mitochondrial protein targeting. The acquisition aims to enhance N2OFF's investment portfolio and enter the lucrative cancer therapeutics market, which is projected to grow from $194.1 billion in 2024 to $344.1 billion by 2031 [1].The acquisition involves N2OFF purchasing shares from existing stakeholders for $700,000 and exchanging additional shares for ownership stakes, ultimately positioning MitoCareX as a wholly owned subsidiary. The agreement includes provisions for milestone-based stock issuances and a commitment from N2OFF to support MitoCareX financially for the first two years post-acquisition. The transaction is expected to close in October 2025, pending final conditions [1].
The approval of the acquisition demonstrates shareholder confidence in N2OFF's strategic direction and growth prospects. However, the acquisition includes terms that may dilute existing shareholders, as the sellers will be entitled to 30% of N2OFF's financing proceeds and milestone-based issuances of up to 25% of common stock. Additionally, the press release reveals a potential conflict of interest, as key individuals from N2OFF are also involved with SciSparc, raising concerns about governance and decision-making transparency regarding the acquisition [1].
N2OFF's commitment to financially support MitoCareX with an initial cash investment of $1,000,000 and ongoing operations support increases the company's financial obligations, which may affect its capital allocation and operational focus [1].
The 15-minute chart for N2OFF on October 1, 2025, at 12:00, indicated a KDJ Death Cross and Bearish Marubozu pattern, suggesting a shift in momentum towards the downside. Sellers are currently in control of the market, and bearish momentum is likely to continue .
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios